Search Results for: covid-19
Articles
FORMULATION FORUM - Formulation & Process of Lipid Nanoparticles for Delivery of Small Molecules & Biologicals January 17, 2022
Jim Huang, PhD, explains how recently, lipid nanoparticles have emerged as a drug delivery system for biologicals, especially for the COVID-19 mRNA vaccines in which LNPs play a vital role in transporting mRNA into the target cells.
ORGAN-ON-A-CHIP - A Novel Way to Accurately Test Delivery of Non-Standard Formulations January 17, 2022
David Hughes, PhD, says ultimately, the goal of OOC technology is to improve the translatability of data between the lab and the clinic. Through a lung-on-a-chip approach, it is possible to recreate the histoarchitecture, phenotype, and function of bronchial and alveolar areas of the lung.
EXOSOMES - The Next Evolution in Therapy Delivery Beyond the Cell Membrane: The Promise of Exosomes January 17, 2022
Linda Marbán, PhD, says perhaps the best way to get past the cell membrane is to deliver contents the same way that cells send information to each other. And that is by the exosome, which in the case of targeted therapy delivery, has been identified as an alternative that shows powerful promise.
Clinical Trial Begins in the UK to Investigate 3-in-1 High Blood Pressure Pill January 17, 2022
George Medicines recently announced its proprietary triple low-dose combination pill, GMRx2, will be trialed in UK patients with high blood...EXECUTIVE INTERVIEW - GATC Health & Liquid Biosciences: Faster, Cheaper, More Effective Drug Discovery January 14, 2022
Ian Jenkins, Director of Science, and Jeff Moses, CMO at GATC Health, discuss the combined benefits of their MAT platform and Liquid Biosciences’ Emerge mathematical evolution platform to help identify the right biology sooner and focus on a smaller set of potential compounds early in the pre-clinical development process to enable pharma companies to develop drugs with more efficiency and a higher success rate.
Proscia & Datavant Partner to Connect Pathology Data With Health Data Ecosystem for Life Sciences R&D January 13, 2022
Proscia and Datavant recently announced a partnership that will provide life sciences companies with digitized pathology data to power the development...Q-VANT Biosciences Launches to Solve the Pharmaceutical Industry Problem of Limited Quillaja Saponin-Based Adjuvants for Life-Saving Vaccines January 12, 2022
Q-VANT Biosciences has launched as the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants including QS-21. QS-21 is considered the “Gold Standard” adjuvant for enhancing immune….
COVAXIN (BBV152) Booster Shown to Neutralize Both Omicron & Delta Variants of SARS-CoV-2 January 12, 2022
Ocugen, Inc.and its partner, Bharat Biotech recently announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of candidate vaccine….
Definitive Agreement to Acquire Exelead Will Strengthen the CDMO Offering for mRNA of the Life Science Business of Merck KGaA, Darmstadt, Germany January 11, 2022
Merck KGaA, Darmstadt, Germany recently announced the signing of a definitive agreement to acquire Exelead, a biopharmaceutical contract development and...Veru Announces FDA Grant of Fast Track Designation for Enobosarm for the Treatment of AR+ ER+ HER2- Metastatic Breast Cancer January 10, 2022
Veru Inc. recently announced the US FDA has granted Fast Track designation to the Phase 3 registration program for the investigation of enobosarm, a selective androgen receptor targeting agonist, for the treatment of….
Moderna Announces First Participant Dosed in Phase 1 Study of its Epstein-Bar Virus Vaccine January 5, 2022
Moderna, Inc. recently announced the first participant has been dosed in the Phase 1 study of mRNA-1189, the Company's Epstein-Barr Virus...Pfizer & BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine January 5, 2022
Pfizer Inc. and BioNTech SE recently announced a new research, development, and commercialization collaboration to develop a potential first mRNA-based vaccine for the prevention of shingles….
Curia Unveils Comprehensive mRNA Solution January 4, 2022
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, recently unveiled its messenger RNA (mRNA) solution, which includes discovery, process development and mRNA drug substance production, through….
FDA Approves First Pill to Treat COVID After Pfizer's Oral Medication Reduced Hospitalizations by 88% in Key Study December 22, 2021
US health regulators recently authorized the first pill against COVID-19, a Pfizer drug that Americans will be able to take at home...Atossa Therapeutics Begins Enrollment of Phase 2 Clinical Study of Oral Endoxifen in Sweden December 22, 2021
Atossa Therapeutics, Inc. recently announced it has initiated enrollment of its Phase 2 clinical study of oral Z-Endoxifen in Sweden....WACKER & CordenPharma Develop Solutions for Formulating Lipid Nanoparticles, Expanding Their Portfolio for Advanced Medicines December 14, 2021
WACKER and CordenPharma have signed a development partnership in the field of Lipid Nanoparticle formulation. The two companies announced they...Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant December 14, 2021
Adagio Therapeutics, Inc. recently provided an update following external in vitro analyses to evaluate neutralizing activity of ADG20 against the...Vaccitech Acquires Avidea Technologies to Expand Product Pipeline & Strengthen Scientific Leadership in Immunotherapies & Vaccines December 13, 2021
Vaccitech plc recently announced that it has acquired US-based Avidea Technologies, Inc. The consideration to Avidea’s existing shareholders is $40 million….
Fareva & ApiJect Sign Licensing Agreement to Create a France-Based 500-Million Unit Annual Capacity for Single-Dose Prefilled Vaccine Injections December 9, 2021
Fareva and ApiJect Systems, Corp. recently announced a 10-year licensing agreement to install three Blow-Fill-Seal production lines that when operational will be able to fill-finish more than 500 million doses per year of vaccines and….
London Heathrow Airport’s CEO, John Holland-Kaye, Pays a Visit to Micropore Technologies December 9, 2021
Following its award as a Global Britain Business Champion by London’s Heathrow Airport, Micropore Technologies was delighted to host a...
